Subtype
Glioma
CI-CAN-00000935Explore in graph →
Non-malignant787 active trials5 approved drugs147 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000935Explore in graph →
Clinical trials
2,805 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT02367482 | Tryptophan Metabolism in Human Brain Tumors-Novocure | completed | — | 20 | Wayne State UniversityOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06885333 | Whole-Brain Tumor Burden Metrics with Inflammatory and Molecular Markers to Predict Postoperative Neurocognitive Decline in Glioma | completed | — | 192 | West China HospitalOTHER | 0 | Mar 20, 2025 | clinicaltrials |
| NCT03893903 | AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma(AMPLIFY-NEOVAC) | completed | Phase 1 | 69 | German Cancer Research CenterOTHER | 1 | Mar 14, 2025 | clinicaltrials |
| NCT05759195 | Biomolecular Analysis for Predicting Response to Regorafenib(RegoRec) | completed | N/A | 53 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05772767 | Modulation of Ciliogenesis in Glioma Stem Cells(RF2019-1236878) | completed | N/A | 100 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Mar 13, 2025 | clinicaltrials |
| NCT02992015 | Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma | completed | Early Phase 1 | 2 | University of Colorado, DenverOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT03344250 | Phase I EGFR BATs in Newly Diagnosed Glioblastoma | completed | Phase 1 | 16 | University of VirginiaOTHER | 1 | Mar 6, 2025 | clinicaltrials |
| NCT04056910 | Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors | completed | Phase 2 | 15 | Jason J. Luke, MDOTHER | 1 | Feb 27, 2025 | clinicaltrials |
| NCT05131815 | The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors | completed | N/A | 8 | Cedars-Sinai Medical CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT01894061 | NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma | completed | Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03481231 | In Situ Immune Parameters and Their Prognostic Role on the Survival of Patients With Glioblastoma(IMMUNOGLIO) | completed | — | 160 | Centre Georges Francois LeclercOTHER | 2 | Feb 17, 2025 | clinicaltrials |
| NCT03576612 | GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas(GMCI) | completed | Phase 1 | 41 | Candel Therapeutics, Inc.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT05140902 | Accurate DCE-MRI Measurement of Glioblastoma Using Point-of-care Portable Perfusion Phantom | completed | N/A | 12 | University of Alabama at BirminghamOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT02078648 | Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 74 | Stemline Therapeutics, Inc.INDUSTRY | 1 | Feb 3, 2025 | clinicaltrials |
| NCT06469138 | A Study to Investigate 14C-bemcentinib in Healthy Male Subjects(8479217) | completed | Phase 1 | 6 | BerGenBio ASAINDUSTRY | 1 | Jan 29, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT03154190 | Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer | completed | N/A | 128 | Stanford UniversityOTHER | 1 | Jan 24, 2025 | clinicaltrials |
| NCT02020720 | 18F-DOPA-PET in Planning Surgery in Patients With Gliomas | completed | Early Phase 1 | 72 | Mayo ClinicOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT02960230 | H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas | completed | Phase 1 / Phase 2 | 50 | Sabine Mueller, MD, PhDOTHER | 2 | Jan 22, 2025 | clinicaltrials |
| NCT05296122 | Safety and Feasibility of MR-guided Laser Thermal Ablation of Brain Lesions | completed | N/A | 14 | Clinical Laserthermia Systems ABINDUSTRY | 1 | Jan 15, 2025 | clinicaltrials |
| NCT02323880 | Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | completed | Phase 1 | 59 | Children's Oncology GroupNETWORK | 1 | Jan 14, 2025 | clinicaltrials |
| NCT02465268 | Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme(ATTAC-II) | completed | Phase 2 | 175 | University of FloridaOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03914742 | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations | completed | Phase 1 / Phase 2 | 67 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT04842513 | Multi Peptide Vaccination with XS15 in Addition to Standard Postoperative Radiation Therapy and Temozolomide Chemotherapy in Newly Diagnosed Glioblastoma(GLIO-XS15) | completed | Phase 1 | 15 | University Hospital TuebingenOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT01849146 | Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma | completed | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04280848 | Anticancer Therapeutic Vaccination Using Telomerase-derived Universal Cancer Peptides in Glioblastoma(UCPVax-Glio) | completed | Phase 2 | 67 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04539574 | An Investigational Scan (7T MRI) for the Imaging of Central Nervous System Tumors | completed | N/A | 50 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 8, 2025 | clinicaltrials |
| NCT01553149 | Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 4 | Jan 7, 2025 | clinicaltrials |
| NCT01752491 | A Phase I Trial of High-Dose Ascorbate in Glioblastoma Multiforme | completed | Phase 1 | 13 | Joseph J. Cullen, MD, FACSOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT04028479 | The Registry of Oncology Outcomes Associated With Testing and Treatment(ROOT) | completed | — | 167 | Taproot HealthINDUSTRY | 1 | Dec 18, 2024 | clinicaltrials |
| NCT02901925 | A Microdose Evaluation Study of ABY-029 in Recurrent Glioma(ABY-029) | completed | Early Phase 1 | 14 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT05015543 | Physical Training in Glioblastoma Patients During Cytotoxic Therapy(MMH) | completed | N/A | 54 | University Hospital MuensterOTHER | 1 | Dec 12, 2024 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01464177 | Hypofractionated Stereotactic Radiotherapy in Recurrent Glioblastoma Multiforme(GBM Hypo RT) | completed | Phase 2 | 40 | Andre Tsin Chih ChenOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT01130077 | A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction with Poly-ICLC in Pediatric Gliomas | completed | Phase 1 | 60 | James FelkerOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT01595139 | MicroRNAs in Patients With Neurofibromatosis Type 1 | completed | — | 9 | Ann & Robert H Lurie Children's Hospital of ChicagoOTHER | 1 | Dec 6, 2024 | clinicaltrials |
| NCT04109209 | Psychological Intervention For Brain Tumor Caregivers | completed | N/A | 120 | Massachusetts General HospitalOTHER | 1 | Dec 5, 2024 | clinicaltrials |
| NCT06713395 | PERMA-Based Intervention on Negative Emotions, Adherence, and Complications in Postoperative Glioma Patients(Glioma) | completed | N/A | 124 | Yang HuangOTHER_GOV | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04267146 | Nivolumab in Combination With Temozolomide and Radiotherapy in Children and Adolescents With Newly Diagnosed High-grade Glioma(NIVOGLIO) | completed | Phase 1 / Phase 2 | 41 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Dec 2, 2024 | clinicaltrials |
| NCT04726397 | UNIty-Based MR-Linac Guided AdapTive RadiothErapy for High GraDe Glioma: a Phase 2 Trial(UNITED) | completed | N/A | 108 | Sunnybrook Health Sciences CentreOTHER | 1 | Nov 29, 2024 | clinicaltrials |
| NCT02530320 | Safety and Efficacy of PD0332991 (Palbociclib), a Cyclin-dependent Kinase 4 and 6 Inhibitor, in Patients With Oligodendroglioma or Recurrent Oligoastrocytoma Anaplastic With the Activity of the Protein RB Preserved | completed | Phase 2 | 34 | Grupo Español de Investigación en NeurooncologíaOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT02549833 | Neo-adjuvant Evaluation of Glioma Lysate Vaccines in WHO Grade II Glioma | completed | Phase 1 | 28 | Jennie TaylorOTHER | 1 | Nov 22, 2024 | clinicaltrials |
| NCT04097535 | Measuring Fatty Acid Oxidation in Gliomas Using 18F-FPIA PET/MRI | completed | — | 11 | Imperial College LondonOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT03232424 | NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma | completed | Phase 1 | 12 | Hackensack Meridian HealthOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT03964909 | Resting-State Functional MRI in Glioma Patients Before and After Surgery | completed | N/A | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2024 | clinicaltrials |
| NCT05062772 | Brain Tumor Intraoperative Ultrasound Database(BraTioUS-DB) | completed | — | 150 | Hospital del Rio HortegaOTHER | 5 | Nov 15, 2024 | clinicaltrials |
| NCT03865355 | Blood and Cerebrospinal Fluid Metabolomic Profile in Glioma Patients | completed | — | 50 | Novosibirsk State UniversityOTHER | 1 | Nov 14, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Mar 20, 2025source: clinicaltrials